Skip to main content
padlock icon - secure page this page is secure

Open Access Hemophagocytic Lymphohistiocytosis

Download Article:
(PDF 547.4 kb)
To investigate the clinical features of adult patients with hemophagocytic lymphohistiocytosis (HLH) and to explore possible risk factors for death, we retrospectively reviewed the medical records of 103 adult HLH patients hospitalized from 1997 to 2012. We analyzed the underlying diseases, clinical characteristics, 1aboratory findings, outcomes, and prognostic factors. The most common cause of HLH was hematologic malignancies (n = 49), followed by infectious diseases (n = 24) and autoimmune disorders (n = 14); 24 cases were of unknown etiology. Eight patients had a combination of underlying diseases. HLH was clinically characterized by high fever (96.1%), splenomegaly (79.6%), hepatomegaly (65.0%), lymphadenopathy (53.4%), proteinuria (31.1%), skin rash (25.2%), gastrointestinal hemorrhage (14.6%), disseminated intravascular coagulation (13.6%), increased creatinine (7.8%), and central nervous system involvement (12.6%) including altered mental status (9.7%) and cranial hemorrhage (2.9%). Laboratory abnormalities included cytopenia (99.0%), serum ferritin >500 ug/L (98.4%), liver dysfunction (98.1%), hypertriglyceridemia (88.5%), hemophagocytosis in bone marrow smear (87.4%), and hypofibrinogenemia (60.9%).

In addition to the treatment they received for the underlying causes, patients received therapy for HLH consisting of corticosteroids, immunosuppressive drugs, and intravenous immunoglobulin. Twenty-six patients (25.2%) recovered after treatment, and 19 of them achieved long-term remission during follow-up. Seventy-seven patients (74.8%) died because of tumor, sepsis, multiple organ failure, or HLH-related organ hemorrhage and coagulopathy. The deceased patients were more likely to be older at disease onset, male, and to present with splenomegaly and thrombocytopenia, compared to the survivors. Treatment for the underlying diseases combined with corticosteroids, immunosuppressive agents, and immunoglobulin therapy may improve the prognosis of HLH. More attention should be paid to high-risk patients to prevent the development of serious complications associated with HLH.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: AOSD = adult-onset Still disease; CMV = cytomegalovirus; CNS = central nervous system; DIC = disseminated intravascular coagulation; EBV = Epstein-Barr virus; HLH = hemophagocytic lymphohistiocytosis; IVIg = intravenous immunoglobulin; MAS = macrophage-activation syndrome; NK = natural killer; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; autoimmune diseases; clinical manifestation; hemophagocytic lymphohistiocytosis; lymphoma; prognosis; risk factor

Document Type: Research Article

Affiliations: From the Department of Rheumatology and Clinical Immunology (JL, QW, W. Zheng, XT), Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing; and Renal Department of Internal Medicine (JM), Hematology Department of Internal Medicine (W. Zhang), and Pathology Department (WW), Peking Union Medical College Hospital, Beijing, China.

Publication date: March 1, 2014

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more